Daily Stock Analysis, CRVS, Corvus Pharmaceuticals Inc, priceseries

Corvus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.10
Close
4.15
High
4.34
Low
4.10
Previous Close
4.19
Daily Price Gain
-0.04
YTD High
8.10
YTD High Date
Jul 5, 2019
YTD Low
3.20
YTD Low Date
Sep 3, 2019
YTD Price Change
-0.12
YTD Gain
-2.81%
52 Week High
10.70
52 Week High Date
Sep 12, 2018
52 Week Low
3.20
52 Week Low Date
Sep 3, 2019
52 Week Price Change
-5.81
52 Week Gain
-58.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
15.57
Apr 4. 2017
20.09
19 Trading Days
29.00%
Link
LONG
May 11. 2017
10.11
May 30. 2017
10.71
12 Trading Days
5.98%
Link
LONG
Aug 23. 2017
13.00
Sep 20. 2017
16.39
19 Trading Days
26.06%
Link
LONG
Dec 22. 2017
10.55
Dec 27. 2017
11.12
2 Trading Days
5.38%
Link
LONG
Mar 6. 2018
9.04
Apr 5. 2018
10.95
21 Trading Days
21.16%
Link
LONG
May 17. 2018
10.07
Jun 4. 2018
11.92
11 Trading Days
18.39%
Link
LONG
Apr 18. 2019
3.95
Apr 30. 2019
4.29
7 Trading Days
8.49%
Link
LONG
Jun 28. 2019
3.74
Jul 16. 2019
5.47
11 Trading Days
46.38%
Link
Company Information
Stock Symbol
CRVS
Exchange
NasdaqGM
Company URL
http://www.corvuspharma.com
Company Phone
(650) 900-4520
CEO
Richard A. Miller
Headquarters
California
Business Address
863 MITTEN ROAD, SUITE 102, BURLINGAME, CA 94010
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001626971
About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel immuno-oncology therapies designed to harness the immune system to attack cancer cells. Its products include CPE-444, an orally administered antagonist of the adenosine A2A receptor; Adenosine production inhibitor; Adenosine A2B antagonist; and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. The company was founded by Richard A. Miller, Leiv Lea, and Joseph J. Buggy in January 27, 2014 and is headquartered in Burlingame, CA.

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.